Analysts Set MaxCyte, Inc. (NASDAQ:MXCT) PT at $5.50

MaxCyte, Inc. (NASDAQ:MXCT) has been assigned an average recommendation of “Hold” from the five ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $5.50.

Several analysts have issued reports on MXCT shares. Craig Hallum lowered their price objective on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research report on Friday, April 24th. Finally, Wall Street Zen raised shares of MaxCyte from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th.

MaxCyte Price Performance

Shares of NASDAQ:MXCT opened at $1.12 on Wednesday. MaxCyte has a 52-week low of $0.64 and a 52-week high of $2.37. The company has a 50 day moving average of $0.96 and a two-hundred day moving average of $1.07. The company has a market capitalization of $119.97 million, a price-to-earnings ratio of -3.03 and a beta of 1.48.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.06. MaxCyte had a negative net margin of 121.16% and a negative return on equity of 20.03%. The company had revenue of $6.22 million during the quarter, compared to the consensus estimate of $7.28 million. On average, equities analysts anticipate that MaxCyte will post -0.3 earnings per share for the current year.

Institutional Trading of MaxCyte

Several large investors have recently bought and sold shares of MXCT. AQR Capital Management LLC grew its position in MaxCyte by 227.3% in the first quarter. AQR Capital Management LLC now owns 95,501 shares of the company’s stock valued at $261,000 after acquiring an additional 66,323 shares in the last quarter. American Century Companies Inc. grew its position in MaxCyte by 10.6% in the second quarter. American Century Companies Inc. now owns 196,686 shares of the company’s stock valued at $429,000 after acquiring an additional 18,848 shares in the last quarter. Prudential Financial Inc. purchased a new position in shares of MaxCyte during the 2nd quarter valued at approximately $26,000. Hsbc Holdings PLC boosted its stake in shares of MaxCyte by 410.2% during the 2nd quarter. Hsbc Holdings PLC now owns 273,218 shares of the company’s stock valued at $598,000 after buying an additional 219,662 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of MaxCyte during the 2nd quarter valued at approximately $282,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.